


10-03-2006



ET

To the Director of the U.S. Patent and Trademark Office

103316045

and documents or the new address(es) below.

1. Name of conveying party(ies)

LaSalle Bank National Association

2. Name and address of receiving party(ies)

Name: First Horizon Pharmaceutical Corporation

Internal Address: Suite 1800

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance/Execution Date(s):

Execution Date(s) September 18, 2006

☐ Assignment

☐ Merger

☐ Security Agreement

☐ Change of Name

☐ Joint Research Agreement

☐ Government Interest Assignment

☐ Executive Order 9424, Confirmatory License

☒ Other Release

Street Address: 5 Concourse Parkway

City: Atlanta

State: Georgia

Country: USA Zip: 30328-5350

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application or patent number(s):

☐ This document is being filed together with a new application.

A. Patent Application No.(s)

B. Patent No.(s)

4999430, 5019395, 5576022, 5091395, 6509492

Additional numbers attached? ☐ Yes ☒ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Gayle D. Grocke

Internal Address: Latham & Watkins LLP

Suite 5800

Street Address: 233 S. Wacker Drive

City: Chicago

State: Illinois Zip: 60606

Phone Number: 312-993-2622

Fax Number: 312-993-9767

Email Address: gayle.grocke@lw.com

6. Total number of applications and patents involved: 5

7. Total fee (37 CFR 1.21(h) & 3.41) \$ 200.00

☐ Authorized to be charged by credit card

☐ Authorized to be charged to deposit account

☒ Enclosed

☐ None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers _____
Expiration Date _____

b. Deposit Account Number _____

Authorized User Name _____

9. Signature:

10/03/2006 DBYRNE 00000001 4999430

01 FEB 2007

200.00.00
Gayle D. Grocke

Signature

Name of Person Signing

9/26/2006

Date

Total number of pages including cover sheet, attachments, and documents: 4

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

PATENT
REEL: 018338 FRAME: 0962

PATENT RELEASE

This Release is granted on this 18th day of September, 2006, by LASALLE BANK NATIONAL ASSOCIATION, as Collateral Agent with principal offices at 135 South LaSalle Street, Chicago, Illinois 60603 ("Agent"), to FIRST HORIZON PHARMACEUTICAL CORPORATION, a Delaware corporation ("Grantor"), as follows:

WITNESSETH

WHEREAS, the Grantor has heretofore granted to the Agent a security interest in certain U.S. patents and patents applications more particularly set forth on Schedule A attached hereto (the "Patents") to secure the Obligations (as defined in the Security Agreement, dated as of February 11, 2003, entered into by the Grantor and various other subsidiaries of the Grantor, in favor or and for the benefit of, inter alia, the Agent, as amended (the "Security Agreement"); and

WHEREAS, the Agent wishes to release and restore all right, title and interest in and to the Patents to the Grantor and to dissolve any and all liens and encumbrances respecting the Patents show on the attached Schedule A hereto.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, the Agent hereby releases, discharges, quit claims and relinquishes unto the Grantor any and all right, title and interest in and to the Patents, and more particularly, the security interest in the patents and patent applications set forth on Schedule A hereto, granted to Agent by the Grantor by the Security Agreement.

IN WITNESS WHEREOF, the undersigned, by and through its authorized officer, has caused this instrument to be executed under seal on the date first written above.

LASALLE BANK NATIONAL ASSOCIATION,
as Collateral Agent

By: Patrick J. O'Toole

Name: Patrick J. O'Toole

Title: First Vice President

SCHEDULE A

<u>Title</u>	<u>Application/Registration No.</u>	<u>Owner</u>
Derivatives of 1,2,3,4-Tetrahydro-9-Acrisinamine	4,999,430	Sciele Pharma, Inc.
Compositions with Enhanced Penetration	5,019,395	Sciele Pharma, Inc.
Controlled Release Tacrine Druge Delivery Systems and Methods for Preparing Same	5,576,022	Sciele Pharma, Inc.
Heterocyclic Compounds and their Pharmaceutical Formulation	5,091,395	First Horizon Pharmaceutical Corporation
Tannate Compositions and Method of Treatment	6,509,492	Sciele Pharma, Inc.